GTC Biotherapeutics' IPO

GTC Biotherapeutics raised a round of funding on September 06, 2005. Investors include Public.

GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. ATryn‚®, GTC‚'s recombinant human antithrombin, has been approve…

Articles about GTC Biotherapeutics' IPO: